MARKET

CYTK

CYTK

Cytokinetics Inc
NASDAQ
32.14
+0.92
+2.95%
After Hours: 32.14 0 0.00% 16:20 11/29 EST
OPEN
31.43
PREV CLOSE
31.22
HIGH
34.11
LOW
31.43
VOLUME
1.80M
TURNOVER
0
52 WEEK HIGH
47.49
52 WEEK LOW
25.98
MARKET CAP
3.15B
P/E (TTM)
-5.8217
1D
5D
1M
3M
1Y
5Y
Investing in Cytokinetics (NASDAQ:CYTK) five years ago would have delivered you a 313% gain
Cytokinetics, incorporated's share price has fallen 11% in the last quarter, but the stock is up 313% over the last five years. The share price is up due to the company's impressive long term performance. In the last 5 years the company has grown its revenue at a rate of 21% per year. The company's fundamentals suggest the stock could be worth buying despite the sell-off.
Simply Wall St · 1d ago
Analysts Offer Insights on Healthcare Companies: Arcutis Biotherapeutics (ARQT), Axsome Therapeutics (AXSM) and Cytokinetics (CYTK)
TipRanks · 1d ago
Weekly Report: what happened at CYTK last week (1120-1124)?
Weekly Report · 3d ago
Analysts Offer Insights on Healthcare Companies: Agilent (A), Cytokinetics (CYTK) and Aligos Therapeutics (ALGS)
TipRanks · 11/22 11:40
Weekly Report: what happened at CYTK last week (1113-1117)?
Weekly Report · 11/20 09:13
Cytokinetics Inc: Current report
Press release · 11/17 21:25
Prospective Growth for Cytokinetics: A Comprehensive Analysis of Aficamten’s Potential and Market Impact
TipRanks · 11/16 12:18
Cytokinetics Inc: Statement of changes in beneficial ownership of securities
Press release · 11/16 03:20
More
About CYTK
Cytokinetics Inc. is a late-stage biopharmaceutical company. The Company is focused on discovering, developing, and commercializing muscle activators and muscle inhibitors as potential treatments for debilitating diseases. It is developing small molecule drug candidates specifically engineered to impact muscle function and contractility. The Company's clinical-stage drug candidates are: omecamtiv mecarbil, a cardiac myosin activator for the treatment of heart failure with reduced ejection fraction (HFrEF); CK-136, a cardiac troponin activator for the treatment of heart failure and other diseases; reldesemtiv , a fast skeletal muscle troponin activator (FSTA) for the treatment of people living with debilitating diseases and conditions associated with muscular weakness; aficamten, a cardiac myosin inhibitor designed to reduce the hypercontractility that is associated with hypertrophic cardiomyopathy (HCM); and CK-136 an novel small molecule cardiac troponin activator.

Webull offers Cytokinetics, Inc. stock information, including NASDAQ: CYTK real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CYTK stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CYTK stock methods without spending real money on the virtual paper trading platform.